Posted by Michael Wonder on 12 Jan 2017
Health Canada approves new heart failure treatment Lancora to reduce mortality and hospitalisations
10 January 2017 - Health Canada has issued a Notice of Compliance for Lancora (ivabradine hydrochloride), a new treatment shown to reduce mortality and hospitalisations in patients suffering from chronic heart failure.
Lancora is a first-in-class treatment which lowers the heart rate, and is indicated on top of standard treatment in stable chronic heart failure patients with a heart rate of 77 beats per minute or higher and with reduced left ventricular ejection fraction (≤ 35%) in NYHA Classes II or III.
